

# Factors Associated with Increased Radial Augmentation Index in Hypertensive Individuals

Renan Oliveira Vaz-de-Melo<sup>1</sup>, Adriana Giubilei Pimenta<sup>1</sup>, Luiz Tadeu Giollo Júnior<sup>1</sup>, Débora Dada Martinelli<sup>1</sup>, Carolina Neves Cosenso Sacomani<sup>1</sup>, Juan Carlos Yugar-Toledo<sup>1</sup>, José Paulo Cipullo<sup>1</sup>, Marco Antônio Mota Gomes<sup>3</sup>, Heitor Moreno Júnior<sup>2</sup>, José Fernando Vilela Martin<sup>1</sup>

Clínica de Hipertensão - Departamento de Medicina Interna, Faculdade de Medicina de São José do Rio Preto - FAMERP¹, São Paulo SP; Laboratório de Farmacologia Cardiovascular – Faculdade de Ciências Médicas - Universidade Estadual de Campinas – UNICAMP², Campinas, SP; Universidade Estadual de Ciências da Saúde de Alagoas – UNCISAL³, Maceió, AL, Brazil

## **Abstract**

Background: Arterial stiffness is a variable predictor of morbidity and mortality and a possible marker of vascular injury. Its non-invasive assessment by radial tonometry and analysis of the augmentation index (r-AI) allows identifying patients exposed to higher cardiovascular risk.

Objective: To analyze the influence of r-AI on clinical-biochemical variables and its influence on the prevalence of targetorgan damage in hypertensive patients.

Methods: 140 consecutive hypertensive patients, followed-up in an outpatient clinic, were analyzed in a cross-sectional study. Blood pressure (BP) levels and r-Al were obtained by applanation tonometry of the radial artery (HEM-9000Al, Onrom). The patients were allocated into r-Al tertiles (r-Al  $\leq$  85%; 85 < r-Al  $\leq$  97%; r-Al > 97%).

Results: The sample was predominantly composed of women (56.4%), mean age of 61.7  $\pm$  11.7 years and body mass index 29.6  $\pm$  6.1 Kg/m². The highest tertile showed higher proportion of women (p = 0.001), higher systolic BP (p = 0.001) and pulse pressure (p = 0.014), and lower weight (p = 0.044), height (p < 0.001) and heart rate (p < 0.001). Multivariate analysis demonstrated that weight ( $\beta$  = -0.001, p = 0.017), heart rate ( $\beta$  = -0.001, p = 0.007) and central pressure ( $\beta$ = 0.015, p < 0.001) correlated independently with r-Al. In logistic regression analyses, the 3rd r-Al tertile was associated to lower levels of diabetes (DM) (OR = 0.41; 95% CI 0.17-0.97; p = 0.042).

Conclusions: This study demonstrated that weight. heart rate and central BP were independently related to r-AI. (Arq Bras Cardiol 2011; 97(3): 241-248)

Keywords: Arteries / physiopathology; blood pressure; elasticity; hypertension; coronary artery disease.

#### Introduction

Since the publication of the Conduit Artery Function Evaluation (CAFE) study<sup>1</sup>, the importance of assessment of arterial function and central blood pressure increased substantially. Despite the fact that brachial blood pressure is a powerful predictor of cardiovascular morbidity and mortality<sup>2</sup>, these measurements do not reflect the pressure in the central circulation. Recent evidence showed that central blood pressure is more relevant to cardiovascular outcomes than pressures in the brachial artery<sup>1,3,4</sup>.

It is well recognized that arterial stiffness parameters predict clinical outcomes, such as coronary artery disease<sup>5,6</sup>, stroke<sup>6</sup>, urinary albumin excretion<sup>7,8</sup>, progression of chronic kidney disease<sup>9</sup>, survival in end-stage renal disease<sup>10</sup> and general

Despite the fact that some variables such as age<sup>19,20</sup>, height<sup>11,18,20</sup>, heart rate<sup>11,19,21-24</sup>, gender<sup>11,18,19,21</sup>, systolic (SBP)20 and diastolic blood pressure (DBP)<sup>11,19,20</sup> have been correlated with the augmentation index, this relationship needs to be better established. Therefore, this study aimed

to access the central pressure 17,18.

to analyze the influence of r-Al on the prevalence of targetorgan damage and to correlate this measure of arterial stiffness with clinical and biochemical variables in Brazilian hypertensive patients.

cardiovascular risk<sup>11</sup>. The current standard for assessing this

condition involves the measurement of several variables

by noninvasive applanation tonometry, including the radial

augmentation index (r-Al)12. r-Al, which is defined as an

increase in pressure from the first systolic shoulder to the

peak pressure of the aortic pressure waveform expressed as

a percentage of peak pressure, has been correlated with left

ventricular hypertrophy (LVH)<sup>13</sup>, coronary artery disease<sup>5</sup>,

urinary albumin excretion<sup>14</sup>, cardiovascular events<sup>15,16</sup> and all-

cause mortality16, representing an easier and quicker method

Mailing Address: Renan Oliveira Vaz-de-Melo •

Rua Professor Enjolrras Vampré. 201 Apt. 44 Bl. 3 - Vila Santa Cândida - 15091-290 - São José do Rio Preto, SP, Brazil

E-mail: renanovmelo@gmail.com

Manuscript received September 13, 2010, revised manuscript received January 27, 2011, accepted March 15. 2011.

#### **Methods**

### **Subjects**

A total of 140 consecutive hypertensive patients, aged  $\geq 18$  years, followed-up in an outpatient clinic from August/2009 to January/2010, were analyzed in a cross-sectional study. The study was previously approved by the Research Ethics Committee of the institution and all participants signed an informed consent. Individuals were allocated to three groups according r-Al tertiles: Group 1 (r-Al  $\leq 85\%$ ) – 44 patients; Group 2 (85 < r-Al  $\leq 97\%$ ) – 47 patients; Group 3 (r-Al > 97%) – 49 patients. The exclusion criteria were: history of atrial fibrillation or frequent supraor ventricular premature beats for which accurate radial waveforms could not be obtained by the system, age  $\geq 70$  years and secondary hypertension.

# Biochemical analysis, demographic data and target-organ damage

Peripheral blood was drawn in fasting for biochemical analysis of serum creatinine, total cholesterol, HDL-cholesterol, triglycerides and glucose. LDL-cholesterol was calculated by the Friedewald formula. Urinary albumin excretion (UAE) was determined by 24-h urine sample, considering normoalbuminuria as UAE < 20  $\mu$ g/min, microalbuminuria as UAE between 20 and 200  $\mu$ g/min and macroalbuminuria as UAE  $\geq$  200  $\mu$ g/min.

For the assessment of comorbidities, data regarding the presence of diabetes mellitus, medications in usage, body mass index [BMI = weight (kg) / height (cm)²], gender and other risk factors or necessary information were obtained from the medical record. Patients with diabetes mellitus (DM) were considered to be those who had been previously on hypoglycemic treatment or having fasting glucose levels ≥ 126 mg/dL on at least two occasions.

The estimated glomerular filtration rate (eGFR) was calculated using the abbreviated MDRD (Modification on Diet in Renal Disease) formula. Renal failure was defined as eGFR  $\leq$  60 mL/min. LVH was determined by echocardiography, the normal left ventricular mass index (LVMI) for men was < 103 g/m² and for women < 89 g/m², as suggested by the American Society of Echocardiography²5.

#### Pulse wave and blood pressure analysis

Arterial pulse waveforms of the left radial artery were measured non-invasively by an automated tonometric system (HEM-9000AI; Omron Healthcare Co., Ltd., Kyoto, Japan) after 10 min of rest in a sitting position<sup>12</sup>. Pulse wave analyses were performed at least three times and the mean of measurements was analyzed. Radial arterial waveforms from this device, the first (P1) and late (second) systolic peaks (P2) were automatically identified using the fourth derivative wave as the second and third zero crossing points, respectively. Augmentation index (AI) was defined as the ratio of the height of P2 to that of P1. Brachial blood pressure (BP) and heart rate were measured simultaneously in the right brachium with an oscillometric

device incorporated into the HEM-9000 Al. Late systolic BP in the radial artery (rSBP2), as an index of central BP $^{26}$ , was calculated by the following equation: rSBP2 = r-Al × (SBP-DBP) + DBP, in which SBP and DBP are brachial systolic and diastolic BP, respectively. All measurements were performed after at least 8-h fasting.

#### Statistical analysis

The calculated size of the sample, admitting a deviation of 1% to reject the hypothesis of nullity, was 122 patients. Previous studies exploring similar issues  $^{7,21}$  analyzed a sample size similar to this study. Descriptive analysis was performed for qualitative variables and quantitative results are presented as mean  $\pm$  standard deviations. To compare the characteristics of patients ANOVA for quantitative and  $\chi 2$  for qualitative variables were used. Univariate and multivariate analyses were performed to assess the determinants of r-Al using various clinical variables. The variables that were statistically significant (p < 0.05) in the univariate analysis were then evaluated in the multivariate analysis. All statistical analyses were performed using the Minitab 16.0 statistical software. For all tests, a p value < 0.05 was considered significant.

#### Results

Table 1 shows the clinical and biochemical characteristics of the patients according to the tertiles of r-Al. There was an increase in the proportion of women into the highest tertile, with increasing levels of SBP and pulse pressure. In contrast, there was a progressive reduction in weight, height and heart rate with increasing r-Al, with no significant differences for biochemical and echocardiographic parameters. There were no differences in the history of diabetes, renal failure, LVH or alterations in urinary albumin excretion among tertiles (Table 2), with the exception of a higher prevalence of LVH in the  $3^{\rm rd}$  tertile of r-Al in relation to the  $2^{\rm rd}$  tertile (p = 0.026).

Using logistic regression analyses (Table 3), the third tertile of r-Al were associated with lower risk of diabetes mellitus (OR = 0.41; 95% Cl 0.17-0.97; p = 0.042). There was no statistical significance (p > 0.05) for LVH and renal failure in the logistic regression.

Univariate (Table 4) and multivariate (Table 5) analyses were performed to assess factors determining r-Al. Univariate analysis showed that weight, height, gender, SBP, DBP, heart rate, pulse pressure, rSBP2 and glucose significantly correlated with r-Al. However, multivariate analysis demonstrated that only weight, heart rate and rSBP2 remained independently correlated with r-Al. Figures 1 and 2 show the relationship between r-Al with the variables that showed significance in the univariate analysis.

### **Discussion**

In this study, we analyzed factors related to r-Al in a sample of hypertensive patients. The measure of arterial compliance through radial artery tonometry is a simple and easier method to assess arterial stiffness<sup>17,18</sup>. Al is strongly correlated with a previously validated estimate of arterial stiffness, pulse wave velocity (PWV)<sup>12,18</sup>. Its use to assess cardiovascular risk and drug effectiveness, as recently reported in the CAFE study,

gives additional data for the stratification of cardiovascular risk and allows clinicians to customize antihypertensive therapies specifically to a single patient<sup>1,2,17</sup>.

Recent reports show that AI is closely related with cardiovascular risk<sup>11,16</sup>. London et al<sup>16</sup> found that the risk ratio for each 10% increase in AI was 1.51 (95% CI 1.23-1.86) for all-cause mortality and 1.48 (95% CI 1.16-1.90) for cardiovascular mortality in a sample of end-stage renal failure patients. Nürnberger et al<sup>11</sup>, on the other hand, found that AI significantly increased with increasing risk scores for cardiovascular disease.

Some studies have shown values that could be considered normal for AI using limits of normality based on the 95% confidence interval. Wojciechowska et al<sup>26</sup> in a European sample, proposed the value for peripheral AI of 90% for men and 100% for women. Shiburi et al<sup>27</sup> in a study which included black South Africans, proposed the thresholds to diagnose increased arterial

stiffness the value at age 30 years of 100% for peripheral AI, with adjustment by 10% for each decade that age differs from 30 years. Li et al<sup>28</sup> in a sample of 924 Chinese patients without cardiovascular disease demonstrated the approximate values for normal peripheral AI of 105% in a 40-year-old patient. Finally, Chung et al<sup>29</sup> demonstrated in a Korean sample that peripheral AI of 100% may be the preliminary reference values. Despite these data, the estimation of reference values for peripheral AI in this Brazilian sample was not possible due to be a hypertensive sample with multiple comorbidities, which would prevent the validation of such data.

According to previous studies, r-Al was significantly related to weight, height<sup>11,18</sup>, gender<sup>11,18,19,21,28-30</sup>, heart rate<sup>11,19,21-23</sup>, SBP<sup>23,30</sup> and DBP<sup>11,19</sup>, pulse pressure and glucose levels in univariate analyses. In this study, this association remained significant only for weight, height and heart rate in multivariate analyses. Body composition affects the timing of

Table 1 - Comparison between clinical and biochemical variables among the tertiles of augmentation index

Age (years)         61.7 ± 11.7         60.4 ± 10.6         61.0 ± 12.4         63.5 ± 12.0         NS           Gender (Male/Female)         61.79         27/17†         23/24‡         11/38         0.001           Weight (Kg)         78.4 ± 17.8         83.4 ± 21.7†         78.0 ± 15.4         74.3 ± 15.1         0.044           Height (M)         1.62 ± 0.09         1.66 ± 0.09†         1.63 ± 0.09‡         1.59 ± 0.06         0.001           Body mass index (Kg/m2)         29.6 ± 6.1         30.2 ± 7.3         29.4 ± 5.2         29.4 ± 5.9         NS           eGFR (ml/min)         55.9 ± 15.8         56.2 ± 16.5         55.8 ± 12.0         55.6 ± 18.5         NS           Diabetes (%)         47.3         56.8†         50.0         34.9         NS           Biochemical parameters         80         116.5 ± 49.9         129.9 ± 66.6         114.5 ± 41.1         106.4 ± 36.9         NS           Biochemical parameters         110.5 ± 49.9         129.9 ± 66.6         114.5 ± 41.1         106.4 ± 36.9         NS           Biochemical parameters         110.5 ± 49.9         129.9 ± 66.6         114.5 ± 41.1         106.4 ± 36.9         NS           Lib-L-cholesterol (mg/dL)         184.3 ± 46.6         185.9 ± 41.7         \$20.± 44.7         \$3.9	Variable	All (n=140)	1 <sup>st</sup> Tertile (n=44) <sup>a</sup>	2 <sup>nd</sup> Tertile (n=47) <sup>b</sup>	3 <sup>rd</sup> Tertile (n=49) <sup>c</sup>	p value*
Weight (Kg)         78.4 ± 17.8         83.4 ± 21.7†         78.0 ± 15.4         74.3 ± 15.1         0.044           Height (m)         1.62 ± 0.09         1.66 ± 0.09†         1.63 ± 0.09‡         1.59 ± 0.06         <0.001           Body mass index (Kg/m2)         29.6 ± 6.1         30.2 ± 7.3         29.4 ± 5.2         29.4 ± 5.9         NS           eGFR (ml/min)         55.9 ± 15.8         56.2 ± 16.5         55.8 ± 12.0         55.6 ± 18.5         NS           Diabetes (%)         47.3         56.8†         50.0         34.9         NS           Biochemical parameters         83.2	Age (years)	61.7 ± 11.7	60.4 ± 10.6	61.0 ± 12.4	63.5 ± 12.0	NS
Height (m)	Gender (Male/Female)	61/79	27/17†	23/24‡	11/38	0.001
Body mass index (Kg/m2)         29.6 ± 6.1         30.2 ± 7.3         29.4 ± 5.2         29.4 ± 5.9         NS           eGFR (ml/min)         55.9 ± 15.8         56.2 ± 16.5         55.8 ± 12.0         55.6 ± 18.5         NS           Diabetes (%)         47.3         56.8 †         50.0         34.9         NS           Biochemical parameters           Glucose (mg/dL)         116.5 ± 49.9         129.9 ± 66.6         114.5 ± 41.1         106.4 ± 36.9         NS           HDL-cholesterol (mg/dL)         53.9 ± 13.8         56.1 ± 15.7         52.0 ± 14.7         53.9 ± 10.7         NS           LDL-cholesterol (mg/dL)         102.1 ± 34.5         102.0 ± 32.3         100.3 ± 37.3         104.0 ± 33.9         NS           Total cholesterol (mg/dL)         184.3 ± 46.6         185.9 ± 41.7         183.1 ± 56.4         183.2 ± 40.8         NS           Triglycerides (mg/dL)         136.9 ± 90.0         139.3 ± 65.1         146.4 ± 132.0         124.9 ± 49.9         NS           Creatinine (mg/dL)         1.4 ± 1.0         1.4 ± 0.4         1.3 ± 0.3         1.5 ± 1.6         NS           Urinary albumin excretion (µg/min)         110.6 ± 389.1         191.5 ± 630.1         72.2 ± 174.1         71.8 ± 191.1         NS           Tomometric paramet	Weight (Kg)	78.4 ± 17.8	83.4 ± 21.7†	78.0 ± 15.4	74.3 ± 15.1	0.044
eGFR (ml/min)         55.9±15.8         56.2±16.5         55.8±12.0         55.6±18.5         NS           Diabetes (%)         47.3         56.8†         50.0         34.9         NS           Biochemical parameters         Biochemical parameters           Glucose (mg/dL)         116.5±49.9         129.9±66.6         114.5±41.1         106.4±36.9         NS           HDL-cholesterol (mg/dL)         53.9±13.8         56.1±15.7         52.0±14.7         53.9±0.7         NS           LDL-cholesterol (mg/dL)         102.1±34.5         102.0±32.3         100.3±37.3         104.0±33.9         NS           Triglycerides (mg/dL)         134.3±46.6         185.9±41.7         183.1±56.4         183.2±40.8         NS           Triglycerides (mg/dL)         136.9±90.0         139.3±65.1         146.4±132.0         124.9±49.9         NS           Creatinine (mg/dL)         1.4±1.0         1.4±0.4         1.3±0.3         1.5±1.6         NS           Urinary albumin excretion (µg/min)         110.6±389.1         191.5±630.1         72.2±174.1         71.8±191.1         NS           Tonometric parameters           SBP (mmHg)         73.4±15.1         70.0±11.2†         73.2±16.0         77.4±16.3         NS           Pulse	Height (m)	1.62 ± 0.09	1.66 ± 0.09†	1.63 ± 0.09‡	1.59 ± 0.06	<0.001
Diabetes (%)         47.3         56.8†         50.0         34.9         NS           Biochemical parameters           Glucose (mg/dL)         116.5 ± 49.9         129.9 ± 66.6         114.5 ± 41.1         106.4 ± 36.9         NS           HDL-cholesterol (mg/dL)         53.9 ± 13.8         56.1 ± 15.7         52.0 ± 14.7         53.9 ± 10.7         NS           LDL-cholesterol (mg/dL)         102.1 ± 34.5         102.0 ± 32.3         100.3 ± 37.3         104.0 ± 33.9         NS           Total cholesterol (mg/dL)         184.3 ± 46.6         185.9 ± 41.7         183.1 ± 56.4         183.2 ± 40.8         NS           Triglycerides (mg/dL)         136.9 ± 90.0         139.3 ± 65.1         146.4 ± 132.0         124.9 ± 49.9         NS           Creatinine (mg/dL)         1.4 ± 1.0         1.4 ± 0.4         1.3 ± 0.3         1.5 ± 1.6         NS           Urinary albumin excretion (µg/min)         110.6 ± 389.1         191.5 ± 630.1         72.2 ± 174.1         71.8 ± 191.1         NS           Tonometric parameters           SBP (mmHg)         131.9 ± 21.8         123.2 ± 17.0†         130.3 ± 20.6‡         140.8 ± 23.6         0.001           DBP (mmHg)         73.4 ± 15.1         70.0 ± 11.2†         73.2 ± 16.0         77.4 ± 16.3         NS     <	Body mass index (Kg/m2)	29.6 ± 6.1	30.2 ± 7.3	29.4 ± 5.2	29.4 ± 5.9	NS
Biochemical parameters	eGFR (ml/min)	55.9 ± 15.8	56.2 ± 16.5	55.8 ± 12.0	55.6 ± 18.5	NS
Glucose (mg/dL)         116.5 ± 49.9         129.9 ± 66.6         114.5 ± 41.1         106.4 ± 36.9         NS           HDL-cholesterol (mg/dL)         53.9 ± 13.8         56.1 ± 15.7         52.0 ± 14.7         53.9 ± 10.7         NS           LDL-cholesterol (mg/dL)         102.1 ± 34.5         102.0 ± 32.3         100.3 ± 37.3         104.0 ± 33.9         NS           Total cholesterol (mg/dL)         184.3 ± 46.6         185.9 ± 41.7         183.1 ± 56.4         183.2 ± 40.8         NS           Triglycerides (mg/dL)         136.9 ± 90.0         139.3 ± 65.1         146.4 ± 132.0         124.9 ± 49.9         NS           Creatinine (mg/dL)         1.4 ± 1.0         1.4 ± 0.4         1.3 ± 0.3         1.5 ± 1.6         NS           Urinary albumin excretion (µg/min)         110.6 ± 389.1         191.5 ± 630.1         72.2 ± 174.1         71.8 ± 191.1         NS           Tonometric parameters           SBP (mmHg)         131.9 ± 21.8         123.2 ± 17.0†         130.3 ± 20.6‡         140.8 ± 23.6         0.001           DBP (mmHg)         73.4 ± 15.1         70.0 ± 11.2†         73.2 ± 16.0         77.4 ± 16.3         NS           Pulse pressure (mmHg)         58.2 ± 16.2         53.3 ± 12.1†         57.1 ± 16.5         63.4 ± 17.7         0.014	Diabetes (%)	47.3	56.8†	50.0	34.9	NS
HDL-cholesterol (mg/dL)  53.9 ± 13.8  56.1 ± 15.7  52.0 ± 14.7  53.9 ± 10.7  NS  LDL-cholesterol (mg/dL)  102.1 ± 34.5  102.0 ± 32.3  100.3 ± 37.3  104.0 ± 33.9  NS  Total cholesterol (mg/dL)  184.3 ± 46.6  185.9 ± 41.7  183.1 ± 56.4  183.2 ± 40.8  NS  Triglycerides (mg/dL)  136.9 ± 90.0  139.3 ± 65.1  146.4 ± 132.0  124.9 ± 49.9  NS  Creatinine (mg/dL)  1.4 ± 1.0  1.4 ± 0.4  1.3 ± 0.3  1.5 ± 1.6  NS  Urinary albumin excretion (μg/min)  110.6 ± 389.1  191.5 ± 630.1  72.2 ± 174.1  71.8 ± 191.1  NS  Tonometric parameters  SBP (mmHg)  131.9 ± 21.8  123.2 ± 17.0†  130.3 ± 20.6 †  140.8 ± 23.6  0.001  DBP (mmHg)  73.4 ± 15.1  70.0 ± 11.2 †  73.2 ± 16.0  77.4 ± 16.3  NS  Pulse pressure (mmHg)  58.2 ± 16.2  53.3 ± 12.1 †  57.1 ± 16.5  63.4 ± 17.7  0.014  Heart rate (beats/min)  70.6 ± 13.7  77.7 ± 15.2 † §  67.4 ± 12.9  67.7 ± 11.0  <0.001  r-Al (%)  91.7 ± 13.3  76.3 ± 7.5 † §  92.1 ± 3.4 ‡  105.4 ± 7.2  <0.001  rSBP1 (mmHg)  129.9 ± 20.9  123.7 ± 16.9 †  129.1 ± 20.6  136.0 ± 23.0  0.026  rSBP2 (mmHg)  216.0 ± 79.9  218.5 ± 87.5  213.8 ± 77.6  216.9 ± 77.3  NS	Biochemical parameters					
LDL-cholesterol (mg/dL)         102.1 ± 34.5         102.0 ± 32.3         100.3 ± 37.3         104.0 ± 33.9         NS           Total cholesterol (mg/dL)         184.3 ± 46.6         185.9 ± 41.7         183.1 ± 56.4         183.2 ± 40.8         NS           Triglycerides (mg/dL)         136.9 ± 90.0         139.3 ± 65.1         146.4 ± 132.0         124.9 ± 49.9         NS           Creatinine (mg/dL)         1.4 ± 1.0         1.4 ± 0.4         1.3 ± 0.3         1.5 ± 1.6         NS           Urinary albumin excretion (µg/min)         110.6 ± 389.1         191.5 ± 630.1         72.2 ± 174.1         71.8 ± 191.1         NS           Tonometric parameters           SBP (mmHg)         131.9 ± 21.8         123.2 ± 17.0†         130.3 ± 20.6‡         140.8 ± 23.6         0.001           DBP (mmHg)         73.4 ± 15.1         70.0 ± 11.2†         73.2 ± 16.0         77.4 ± 16.3         NS           Pulse pressure (mmHg)         58.2 ± 16.2         53.3 ± 12.1†         57.1 ± 16.5         63.4 ± 17.7         0.014           Heart rate (beats/min)         70.6 ± 13.7         77.7 ± 15.2†§         67.4 ± 12.9         67.7 ± 11.0         <0.001	Glucose (mg/dL)	116.5 ± 49.9	129.9 ± 66.6	114.5 ± 41.1	106.4 ± 36.9	NS
Total cholesterol (mg/dL)  184.3 ± 46.6  185.9 ± 41.7  183.1 ± 56.4  183.2 ± 40.8  NS  Triglycerides (mg/dL)  136.9 ± 90.0  139.3 ± 65.1  146.4 ± 132.0  124.9 ± 49.9  NS  Creatinine (mg/dL)  14. ± 1.0  14. ± 0.4  13. ± 0.3  1.5 ± 1.6  NS  Urinary albumin excretion (μg/min)  110.6 ± 389.1  191.5 ± 630.1  72.2 ± 174.1  71.8 ± 191.1  NS  Tonometric parameters  SBP (mmHg)  131.9 ± 21.8  123.2 ± 17.0 †  130.3 ± 20.6 ‡  140.8 ± 23.6  0.001  DBP (mmHg)  73.4 ± 15.1  70.0 ± 11.2 †  73.2 ± 16.0  77.4 ± 16.3  NS  Pulse pressure (mmHg)  58.2 ± 16.2  53.3 ± 12.1 †  57.1 ± 16.5  63.4 ± 17.7  0.014  Heart rate (beats/min)  70.6 ± 13.7  77.7 ± 15.2 † §  67.4 ± 12.9  67.7 ± 11.0  <0.001  rSBP1 (mmHg)  129.9 ± 20.9  123.7 ± 16.9 †  129.1 ± 20.6  136.0 ± 23.0  0.026  rSBP2 (mmHg)  125.0 ± 20.9  110.3 ± 15.0 †  123.9 ± 20.1 ‡  138.4 ± 23.2  <0.001  Echocardiographic parameters  Left ventricular mass (g)  216.0 ± 79.9  218.5 ± 87.5  213.8 ± 77.6  216.9 ± 77.3  NS	HDL-cholesterol (mg/dL)	53.9 ± 13.8	56.1 ± 15.7	52.0 ± 14.7	53.9 ± 10.7	NS
Triglycerides (mg/dL) $136.9 \pm 90.0$ $139.3 \pm 65.1$ $146.4 \pm 132.0$ $124.9 \pm 49.9$ NS           Creatinine (mg/dL) $1.4 \pm 1.0$ $1.4 \pm 0.4$ $1.3 \pm 0.3$ $1.5 \pm 1.6$ NS           Urinary albumin excretion (µg/min) $110.6 \pm 389.1$ $191.5 \pm 630.1$ $72.2 \pm 174.1$ $71.8 \pm 191.1$ NS           Tonometric parameters           SBP (mmHg) $131.9 \pm 21.8$ $123.2 \pm 17.0$ † $130.3 \pm 20.6$ ‡ $140.8 \pm 23.6$ $0.001$ DBP (mmHg) $73.4 \pm 15.1$ $70.0 \pm 11.2$ ‡ $73.2 \pm 16.0$ $77.4 \pm 16.3$ NS           Pulse pressure (mmHg) $58.2 \pm 16.2$ $53.3 \pm 12.1$ ‡ $57.1 \pm 16.5$ $63.4 \pm 17.7$ $0.014$ Heart rate (beats/min) $70.6 \pm 13.7$ $77.7 \pm 15.2$ †§ $67.4 \pm 12.9$ $67.7 \pm 11.0$ $<0.001$ r-Al (%) $91.7 \pm 13.3$ $76.3 \pm 7.5$ †§ $92.1 \pm 3.4$ ‡ $105.4 \pm 7.2$ $<0.001$ rSBP1 (mmHg) $129.9 \pm 20.9$ $123.7 \pm 16.9$ † $129.1 \pm 20.6$ $136.0 \pm 23.0$ $0.026$ rSBP2 (mmHg) $125.0 \pm 20.9$ $110.3 \pm 15.0$ †§ $123.9 \pm 20.1$ ‡	LDL-cholesterol (mg/dL)	102.1 ± 34.5	102.0 ± 32.3	100.3 ± 37.3	104.0 ± 33.9	NS
Creatinine (mg/dL) $1.4 \pm 1.0$ $1.4 \pm 0.4$ $1.3 \pm 0.3$ $1.5 \pm 1.6$ NS           Urinary albumin excretion (µg/min) $110.6 \pm 389.1$ $191.5 \pm 630.1$ $72.2 \pm 174.1$ $71.8 \pm 191.1$ NS           Tonometric parameters           SBP (mmHg) $131.9 \pm 21.8$ $123.2 \pm 17.0 \uparrow$ $130.3 \pm 20.6 \ddagger$ $140.8 \pm 23.6$ $0.001$ DBP (mmHg) $73.4 \pm 15.1$ $70.0 \pm 11.2 \uparrow$ $73.2 \pm 16.0$ $77.4 \pm 16.3$ NS           Pulse pressure (mmHg) $58.2 \pm 16.2$ $53.3 \pm 12.1 \uparrow$ $57.1 \pm 16.5$ $63.4 \pm 17.7$ $0.014$ Heart rate (beats/min) $70.6 \pm 13.7$ $77.7 \pm 15.2 \uparrow \$$ $67.4 \pm 12.9$ $67.7 \pm 11.0$ $<0.001$ r-Al (%) $91.7 \pm 13.3$ $76.3 \pm 7.5 \uparrow \$$ $92.1 \pm 3.4 \ddagger$ $105.4 \pm 7.2$ $<0.001$ rSBP1 (mmHg) $129.9 \pm 20.9$ $123.7 \pm 16.9 \uparrow$ $129.1 \pm 20.6$ $136.0 \pm 23.0$ $<0.026$ rSBP2 (mmHg) $125.0 \pm 20.9$ $110.3 \pm 15.0 \uparrow \$$ $123.9 \pm 20.1 \ddagger$ $138.4 \pm 23.2$ $<0.001$ Echocardiographic parameters           Left ventricular ma	Total cholesterol (mg/dL)	184.3 ± 46.6	185.9 ± 41.7	183.1 ± 56.4	183.2 ± 40.8	NS
Urinary albumin excretion (μg/min) $110.6\pm389.1$ $191.5\pm630.1$ $72.2\pm174.1$ $71.8\pm191.1$ NS         Tonometric parameters         SBP (mmHg) $131.9\pm21.8$ $123.2\pm17.0\uparrow$ $130.3\pm20.6\ddagger$ $140.8\pm23.6$ $0.001$ DBP (mmHg) $73.4\pm15.1$ $70.0\pm11.2\uparrow$ $73.2\pm16.0$ $77.4\pm16.3$ NS         Pulse pressure (mmHg) $58.2\pm16.2$ $53.3\pm12.1\uparrow$ $57.1\pm16.5$ $63.4\pm17.7$ $0.014$ Heart rate (beats/min) $70.6\pm13.7$ $77.7\pm15.2\uparrow\$$ $67.4\pm12.9$ $67.7\pm11.0$ $<0.001$ r-AI (%) $91.7\pm13.3$ $76.3\pm7.5\uparrow\$$ $92.1\pm3.4\ddagger$ $105.4\pm7.2$ $<0.001$ rSBP1 (mmHg) $129.9\pm20.9$ $123.7\pm16.9\uparrow$ $129.1\pm20.6$ $136.0\pm23.0$ $0.026$ rSBP2 (mmHg) $125.0\pm20.9$ $110.3\pm15.0\uparrow\$$ $123.9\pm20.1\ddagger$ $138.4\pm23.2$ $<0.001$ Echocardiographic parameters         Left ventricular mass (g) $216.0\pm79.9$ $218.5\pm87.5$ $213.8\pm77.6$ $216.9\pm77.3$ NS	Triglycerides (mg/dL)	136.9 ± 90.0	139.3 ± 65.1	146.4 ± 132.0	124.9 ± 49.9	NS
Tonometric parameters           SBP (mmHg) $131.9 \pm 21.8$ $123.2 \pm 17.0 \uparrow$ $130.3 \pm 20.6 \ddagger$ $140.8 \pm 23.6$ $0.001$ DBP (mmHg) $73.4 \pm 15.1$ $70.0 \pm 11.2 \uparrow$ $73.2 \pm 16.0$ $77.4 \pm 16.3$ NS           Pulse pressure (mmHg) $58.2 \pm 16.2$ $53.3 \pm 12.1 \uparrow$ $57.1 \pm 16.5$ $63.4 \pm 17.7$ $0.014$ Heart rate (beats/min) $70.6 \pm 13.7$ $77.7 \pm 15.2 \uparrow \$$ $67.4 \pm 12.9$ $67.7 \pm 11.0$ $<0.001$ r-Al (%) $91.7 \pm 13.3$ $76.3 \pm 7.5 \uparrow \$$ $92.1 \pm 3.4 \ddagger$ $105.4 \pm 7.2$ $<0.001$ rSBP1 (mmHg) $129.9 \pm 20.9$ $123.7 \pm 16.9 \uparrow$ $129.1 \pm 20.6$ $136.0 \pm 23.0$ $0.026$ rSBP2 (mmHg) $125.0 \pm 20.9$ $110.3 \pm 15.0 \uparrow \$$ $123.9 \pm 20.1 \ddagger$ $138.4 \pm 23.2$ $<0.001$ Echocardiographic parameters           Left ventricular mass (g) $216.0 \pm 79.9$ $218.5 \pm 87.5$ $213.8 \pm 77.6$ $216.9 \pm 77.3$ NS	Creatinine (mg/dL)	1.4 ± 1.0	1.4 ± 0.4	1.3 ± 0.3	1.5 ± 1.6	NS
SBP (mmHg) $131.9 \pm 21.8$ $123.2 \pm 17.0 \uparrow$ $130.3 \pm 20.6 \ddagger$ $140.8 \pm 23.6$ $0.001$ DBP (mmHg) $73.4 \pm 15.1$ $70.0 \pm 11.2 \uparrow$ $73.2 \pm 16.0$ $77.4 \pm 16.3$ NS         Pulse pressure (mmHg) $58.2 \pm 16.2$ $53.3 \pm 12.1 \uparrow$ $57.1 \pm 16.5$ $63.4 \pm 17.7$ $0.014$ Heart rate (beats/min) $70.6 \pm 13.7$ $77.7 \pm 15.2 \uparrow \$$ $67.4 \pm 12.9$ $67.7 \pm 11.0$ $<0.001$ r-Al (%) $91.7 \pm 13.3$ $76.3 \pm 7.5 \uparrow \$$ $92.1 \pm 3.4 \ddagger$ $105.4 \pm 7.2$ $<0.001$ rSBP1 (mmHg) $129.9 \pm 20.9$ $123.7 \pm 16.9 \uparrow$ $129.1 \pm 20.6$ $136.0 \pm 23.0$ $0.026$ rSBP2 (mmHg) $125.0 \pm 20.9$ $110.3 \pm 15.0 \uparrow \$$ $123.9 \pm 20.1 \ddagger$ $138.4 \pm 23.2$ $<0.001$ Echocardiographic parameters         Left ventricular mass (g) $216.0 \pm 79.9$ $218.5 \pm 87.5$ $213.8 \pm 77.6$ $216.9 \pm 77.3$ NS	Urinary albumin excretion (µg/min)	110.6± 389.1	191.5 ± 630.1	72.2 ± 174.1	71.8 ± 191.1	NS
DBP (mmHg) $73.4 \pm 15.1$ $70.0 \pm 11.2 \uparrow$ $73.2 \pm 16.0$ $77.4 \pm 16.3$ NS         Pulse pressure (mmHg) $58.2 \pm 16.2$ $53.3 \pm 12.1 \uparrow$ $57.1 \pm 16.5$ $63.4 \pm 17.7$ $0.014$ Heart rate (beats/min) $70.6 \pm 13.7$ $77.7 \pm 15.2 \uparrow \$$ $67.4 \pm 12.9$ $67.7 \pm 11.0$ $<0.001$ r-Al (%) $91.7 \pm 13.3$ $76.3 \pm 7.5 \uparrow \$$ $92.1 \pm 3.4 \ddagger$ $105.4 \pm 7.2$ $<0.001$ rSBP1 (mmHg) $129.9 \pm 20.9$ $123.7 \pm 16.9 \uparrow$ $129.1 \pm 20.6$ $136.0 \pm 23.0$ $0.026$ rSBP2 (mmHg) $125.0 \pm 20.9$ $110.3 \pm 15.0 \uparrow \$$ $123.9 \pm 20.1 \ddagger$ $138.4 \pm 23.2$ $<0.001$ Echocardiographic parameters         Left ventricular mass (g) $216.0 \pm 79.9$ $218.5 \pm 87.5$ $213.8 \pm 77.6$ $216.9 \pm 77.3$ NS	Tonometric parameters					
Pulse pressure (mmHg) $58.2 \pm 16.2$ $53.3 \pm 12.1 \uparrow$ $57.1 \pm 16.5$ $63.4 \pm 17.7$ $0.014$ Heart rate (beats/min) $70.6 \pm 13.7$ $77.7 \pm 15.2 \uparrow \$$ $67.4 \pm 12.9$ $67.7 \pm 11.0$ $<0.001$ r-Al (%) $91.7 \pm 13.3$ $76.3 \pm 7.5 \uparrow \$$ $92.1 \pm 3.4 \ddagger$ $105.4 \pm 7.2$ $<0.001$ rSBP1 (mmHg) $129.9 \pm 20.9$ $123.7 \pm 16.9 \uparrow$ $129.1 \pm 20.6$ $136.0 \pm 23.0$ $0.026$ rSBP2 (mmHg) $125.0 \pm 20.9$ $110.3 \pm 15.0 \uparrow \$$ $123.9 \pm 20.1 \ddagger$ $138.4 \pm 23.2$ $<0.001$ Echocardiographic parameters         Left ventricular mass (g) $216.0 \pm 79.9$ $218.5 \pm 87.5$ $213.8 \pm 77.6$ $216.9 \pm 77.3$ NS	SBP (mmHg)	131.9 ± 21.8	123.2 ± 17.0†	130.3 ± 20.6‡	140.8 ± 23.6	0.001
Heart rate (beats/min) $70.6 \pm 13.7$ $77.7 \pm 15.2 \uparrow \S$ $67.4 \pm 12.9$ $67.7 \pm 11.0$ <0.001 r-Al (%) $91.7 \pm 13.3$ $76.3 \pm 7.5 \uparrow \S$ $92.1 \pm 3.4 \ddagger$ $105.4 \pm 7.2$ <0.001 rSBP1 (mmHg) $129.9 \pm 20.9$ $123.7 \pm 16.9 \uparrow$ $129.1 \pm 20.6$ $136.0 \pm 23.0$ 0.026 rSBP2 (mmHg) $125.0 \pm 20.9$ $110.3 \pm 15.0 \uparrow \S$ $123.9 \pm 20.1 \ddagger$ $138.4 \pm 23.2$ <0.001  Echocardiographic parameters  Left ventricular mass (g) $216.0 \pm 79.9$ $218.5 \pm 87.5$ $213.8 \pm 77.6$ $216.9 \pm 77.3$ NS	DBP (mmHg)	73.4 ± 15.1	70.0 ± 11.2†	73.2 ± 16.0	77.4 ± 16.3	NS
r-Al (%) 91.7 $\pm$ 13.3 76.3 $\pm$ 7.5 $\uparrow$ § 92.1 $\pm$ 3.4 $\ddagger$ 105.4 $\pm$ 7.2 <0.001 rSBP1 (mmHg) 129.9 $\pm$ 20.9 123.7 $\pm$ 16.9 $\dagger$ 129.1 $\pm$ 20.6 136.0 $\pm$ 23.0 0.026 rSBP2 (mmHg) 125.0 $\pm$ 20.9 110.3 $\pm$ 15.0 $\dagger$ § 123.9 $\pm$ 20.1 $\ddagger$ 138.4 $\pm$ 23.2 <0.001 Echocardiographic parameters  Left ventricular mass (g) 216.0 $\pm$ 79.9 218.5 $\pm$ 87.5 213.8 $\pm$ 77.6 216.9 $\pm$ 77.3 NS	Pulse pressure (mmHg)	58.2 ± 16.2	53.3 ± 12.1†	57.1 ± 16.5	63.4 ± 17.7	0.014
rSBP1 (mmHg) $129.9 \pm 20.9$ $123.7 \pm 16.9 \uparrow$ $129.1 \pm 20.6$ $136.0 \pm 23.0$ $0.026$ rSBP2 (mmHg) $125.0 \pm 20.9$ $110.3 \pm 15.0 \uparrow \S$ $123.9 \pm 20.1 \ddagger$ $138.4 \pm 23.2$ $<0.001$ Echocardiographic parameters           Left ventricular mass (g) $216.0 \pm 79.9$ $218.5 \pm 87.5$ $213.8 \pm 77.6$ $216.9 \pm 77.3$ NS	Heart rate (beats/min)	70.6 ± 13.7	77.7 ± 15.2†§	67.4 ± 12.9	67.7 ± 11.0	<0.001
rSBP2 (mmHg)	r-AI (%)	91.7 ± 13.3	76.3 ± 7.5†§	92.1 ± 3.4‡	105.4 ± 7.2	<0.001
Echocardiographic parameters  Left ventricular mass (g) $216.0 \pm 79.9$ $218.5 \pm 87.5$ $213.8 \pm 77.6$ $216.9 \pm 77.3$ NS	rSBP1 (mmHg)	129.9 ± 20.9	123.7 ±16.9†	129.1 ± 20.6	136.0 ± 23.0	0.026
Left ventricular mass (g) 216.0 ± 79.9 218.5 ± 87.5 213.8 ± 77.6 216.9 ± 77.3 NS	rSBP2 (mmHg)	125.0 ± 20.9	110.3±15.0†§	123.9± 20.1‡	138.4 ± 23.2	<0.001
	Echocardiographic parameters					
Left ventricular mass index $(g/m^2)$ 117.3 ± 40.7 112.8 ± 50.0 111.8 ± 39.2 123.5 ± 37.2 NS	Left ventricular mass (g)	216.0 ± 79.9	218.5 ± 87.5	213.8 ± 77.6	216.9 ± 77.3	NS
	Left ventricular mass index (g/m²)	117.3 ± 40.7	112.8 ± 50.0	111.8 ± 39.2	123.5 ± 37.2	NS

Values are expressed as numbers with the percentages in parentheses or mean ± SD. NS – Not significant (p>0.05); eGFR – estimated glomerular filtration rate; SBP – systolic blood pressure; DBP – diastolic blood pressure; r-AI – radial augmentation index; rSBP1 - First systolic BP in the radial artery; rSBP2 – Late systolic BP in the radial artery (central pressure); (\*) ANOVA test; (†) 1st vs. 3rd tertile. p<0.05; (‡) 2nd vs. 3rd tertile. p<0.05; (§) 1st vs. 2nd tertile. p<0.05.

arterial wave reflection, explaining the correlation between r-Al and weight and height<sup>31</sup>. Gatzka et al<sup>32</sup> studied pairs of older men and women matched by age, BMI, and BP levels, and found that women had stiffer elastic arteries, suggesting an effect of female hormonal status in this relationship<sup>31</sup>.

Other factors previously related to AI levels, such as age<sup>19,29,30</sup>, BMI<sup>30</sup>, creatinine clearance<sup>30</sup>, hiperlipidemia<sup>29,30</sup> and LVMI<sup>21</sup> were not associated with r-AI levels in this sample. Aging is associated with histological changes in walls of systemic arteries, mainly in the intima and the in the media. These structural changes in the elastic arteries cause

an increase in both stiffness and resistance<sup>31</sup>, explaining the relationship between Al and age.

There was no association between tertiles of r-Al and prevalence of the target-organ damage analyzed (renal failure, LVH and micro/macroalbuminuria). Despite this, there are reports that Al was associated with coronary artery disease<sup>5</sup>, urinary albumin excretion<sup>14</sup> and LVH<sup>13</sup>, suggesting a relationship between Al and target-organ damage. In relation to LVH, we found a high prevalence in this sample possibly due to the cutoff point adopted by the American Society of Echocardiography for its diagnosis<sup>25</sup>. The attenuation of the

Table 2 - Prevalence of target-organ damage according to tertiles of augmentation index

Variable	1 <sup>st</sup> Tertile (n=44) <sup>a</sup>	2 <sup>nd</sup> Tertile (n=47) <sup>b</sup>	3 <sup>rd</sup> Tertile (n=49)°	p value*
Renal dysfunction (%)	57.1	64.4	57.8	NS
Left ventricular hypertrophy (%)	69.7	66.7†	87.8†	NS
Urinary albumin excretion			-	
Normoalbuminuria (%)	42.9	61.9	56.8	
Microalbuminuria (%)	40.5	26.2	36.4	NS
Macroalbuminuria (%)	16.7	11.9	6.8	

NS – Not significant (p > 0.05); (\*)  $\chi 2$  test; (†) 2nd vs. 3rd tertile, p = 0.026.




Figure 1 – Relationship between radial augmentation index with height. weight. systolic and diastolic blood pressure.

cushioning of elastic arteries amplifies the pressure pulsatility and increases the transmission of pulsatile energy to the peripheral microcirculation<sup>33</sup>. This occurs particularly in high-blood flow

organs, such as brain and kidney, where pressure pulsatility penetrates further into the microcirculation, causing damage to these organs<sup>33,34</sup>.




Figure 2 - Relationship between radial augmentation index with heart rate. pulse pressure and glucose levels.

Table 3 – Logistic regression analyses for diabetes and target-organ damages and tertiles of augmentation index

Variable	β	SE	Odds ratio (95% CI)	Valor p
Diabetes mellitus				
1 <sup>st</sup> Tertile	-	-	1.00	-
2 <sup>nd</sup> Tertile	-0.274	0.428	0.76 (0.33-1.76)	NS
3 <sup>rd</sup> Tertile	-0.898	0.441	0.41 (0.17-0.97)	0.042
Left ventricular hypertrophy				
1 <sup>st</sup> Tertile	-	-	1.00	-
2 <sup>nd</sup> Tertile	-0.139	0.518	0.87 (0.31-2.40)	NS
<sup>3rd</sup> Tertile	1.411	0.609	3.13 (0.95-10.33)	NS
Renal dysfunction				
1 <sup>st</sup> Tertile	-	-	1.00	-
2 <sup>nd</sup> Tertile	0.307	0.440	1.36 (0.57-3.22)	NS
3 <sup>rd</sup> Tertile	0.025	0.433	1.03 (0.44-2.40)	NS

NS - Not significant (p > 0.05).

In relation to glucose metabolism status, we found an inverse relation between glucose levels and r-AI in the univariate analysis. However, when multivariate analyses are performed, this relationship is not present. Further, in the logistic regression, the 3<sup>rd</sup> tertile of r-Al was associated with lower prevalence of DM (OR = 0.41, 95% CI 0.17-0.97, p = 0.042). Studies of the association between type 2 DM and AI are inconclusive. Similarly to our results, Tomita et al<sup>35</sup> found in a sample of type 2 diabetic patients a negative association of r-Al to plasma glucose and HbA1c. Lacy et al<sup>36</sup> in a multiple regression analysis revealed that DM is a significant determinant of PWV, but not of Al. Guiadoni et al<sup>37</sup> also did not found any difference for Al between normotensive patients with and without metabolic syndrome. This same trend was observed by Wilhelm et al in a comparison between type 2 DM and controls<sup>38</sup>. On the other hand, Wilkinson et al<sup>39</sup> showed that AI was significantly high in diabetic patients compared with controls matched by sex, age, weight and height. Despite the fact that there was no difference

Table 4 – Correlation coefficients of augmentation index with clinical-biochemical variables

Variable	r	p value
Age (years)	0.116	NS
Weight (Kg)	-0.325	< 0.001
Height (m)	-0.389	< 0.001
Gender (female)	0.343	< 0.001
Body mass index (Kg/m²)	-0.143	NS
SBP (mm Hg)	0.275	0.002
DBP (mm Hg)	0.187	0.036
HR (beats/min)	-0.298	0.001
rSBP2 (mmHg)	0.477	< 0.001
PP (mm Hg)	0.197	0.027
Total cholesterol (mg/dL)	-0.020	NS
LDL-cholesterol (mg/dL)	-0.020	NS
HDL-cholesterol (mg/dL)	-0.011	NS
Triglycerides (mg/dL)	-0.033	NS
Creatinine (mg/dL)	0.041	NS
Glucose (mg/dL)	-0.203	0.020
Urinary albumin excretion (µg/min)	-0.154	NS
Creatinine clearance (ml/min)	-0.022	NS
Left ventricular mass (g)	-0.008	NS
Left ventricular mass index (g/m²)	0.130	NS

SBP – systolic blood pressure; DBP – diastolic blood pressure; HR – Heart rate; rSBP2 – Late systolic BP in the radial artery (central pressure); PP – Pulse pressure; NS – Not significant (p > 0.05).

for AI between patients with impaired glucose metabolism and normoglicemic controls, Schram et al  $^{\rm 40}$  found a higher aortic AI in patients with DM compared to normoglicemic controls. However, our study cannot provide evidence for these mechanisms. The relationship between r-AI and lower prevalence of DM may have simply coexisted.

This study has some limitations that deserve to be mentioned. Firstly, its cross-sectional design and relative small number of patients does not allow the investigation of the relationship between AI and primary outcomes (stroke and myocardial infarction). Secondly, the AI could have been influenced by heart rate. Therefore, although we did not adjust AI for heart rate, we measured it after 10 minutes of rest. Thirdly, due the fact of our service is a specialized outpatient clinic, we could not assess patients with newly diagnosed hypertension and without antihypertensive treatment for this study.

In conclusion, in our country, this is one of the pioneering studies evaluating the importance of central BP and markers of arterial stiffness (r-Al) in Brazilian hypertensive individuals. In this sample, weight, heart rate and central BP were independently related to r-Al.

#### **Potential Conflict of Interest**

No potential conflict of interest relevant to this article was reported.

## **Sources of Funding**

This study was funded by CAPES, CNPq, FAPESP and Faculdade de Medicina de São José do Rio Preto/Hospital de Base - FUNFARME.

## **Study Association**

This study is not associated with any post-graduation program.

Table 5 – Multivariate relation between augmentation index and clinicalbiochemical variables

Variable	ß	SEβ	p value	
Weight (Kg)	-0.001	0.001	0.017	
Height (m)	-0.019	0.089	NS	
Gender	0.010	0.015	NS	
SBP (mm Hg)	-0.011	0.020	NS	
DBP (mm Hg)	-0.002	0.020	NS	
HR (beats/min)	-0.001	0.001	0.007	
PP (mm Hg)	-0.001	0.020	NS	
rSBP2 (mmHg)	0.015	0.001	< 0.001	
Glucose (mg/dL)	0.001	0.001	NS	

SBP – systolic blood pressure; DBP – diastolic blood pressure; HR – Heart rate; PP – Pulse pressure; rSBP2 – Late systolic BP in the radial artery (central pressure); NS – Not significant (p > 0.05).

## References

- Williams B, Lacy PS, Thom SM, Cruickshank K, Stanton A, Collier D, et al. Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes: principal results of the Conduit Artery Function Evaluation (CAFE) study. Circulation. 2006;113(9):1213-25.
- Protogerou AD, Papaioannou TG, Blacher J, Papamichael CM, Lekakis JP, Safar ME. Central blood pressures: do we need them in the management of cardiovascular disease? Is it a feasible therapeutic target? J Hypertens. 2007;25(2):265-72.
- Roman MJ, Devereux RB, Kizer JR, Lee ET, Galloway JM, Ali T, et al. Central pressure more strongly relates to vascular disease and outcome than does brachial pressure: the Strong Heart Study. Hypertension. 2007;50(1):197-203.
- Safar ME, Blacher J, Pannier B, Guerin AP, Marchais SJ, Guvonvarc'h PM, et al. Central pulse pressure and mortality in end-stage renal disease. Hypertension. 2002;39(3):735-8.
- Weber T, Auer J, O'Rourke MF, Kvas E, Lassnig E, Berent R, et al. Arterial stiffness, wave reflections, and the risk of coronary artery disease. Circulation. 2004;109(2):184-9.
- Mattace-Raso FU, van der Cammen TJ, Hofman A, van Popele NM, Bos ML, Schalekamp MA, et al. Arterial stiffness and risk of coronary heart disease and stroke: the Rotterdam Study. Circulation. 2006;113(5):657-63.
- Mulè G, Cottone S, Cusimano P, Riccobene R, Palermo A, Geraci C, et al. The association of microalbuminuria with aortic stiffness is independent of c-reactive protein in essential hypertension. Am J Hypertens. 2009;22(10):1041-7.
- Hermans MM, Henry R, Dekker JM, Kooman JP, Kostense PJ, Nijpels G, et al. Estimated glomerular filtration rate and urinary albumin excretion are independently associated with greater arterial stiffness: The Hoorn study. J Am Soc Nephrol. 2007;18(6):1942-52.
- Takenaka T, Mimura T, Kanno Y, Suzuki H. Qualification of arterial stiffness as a risk factor to the progression of chronic kidney disease. Am J Nephrol. 2005;25(5):417-24.
- Blacher J, Guerin AP, Pannier B, Marchais SJ, Safar ME, London GM. Impact of aortic stiffness on survival in end-stage renal disease. Circulation. 1999;99(18):2434-9.
- Nürnberger J, Keflioglu-Scheiber A, Opazo Saez AM, Wenzel RR, Philipp T, Schäfers RF. Augmentation index is associated with cardiovascular risk. J Hypertens. 2002;20(12):2407-14.
- DeLoach SS, Townsend RR. Vascular stiffness: its measurements and significance for epidemiologic and outcome studies. Clin J Am Soc Nephrol. 2008;3(1):184-92.
- Hashimoto J, Watabe D, Hatanaka R, Hanasawa T, Metoki H, Asayyama K, et al. Enhanced radial late systolic pressure augmentation in hypertensive patients with left ventricular hypertrophy. Am J Hypertens. 2006;19(1):27-32.
- Tsioufis C, Tzioumis C, Marinakis N, Toutouzas K, Tousoulis D, Kallikazaros I, et al. Microalbuminuria is closely related to impaired arterial elasticity in untreated patients with essential hypertension. Nephron Clin Pract. 2003;93(3):c106-11.
- Weber T, O'rourke MF, Lassnig E, Parodko M, Ammer M, Rammer M, et al. Pulse waveform characteristics predict cardiovascular events and mortality in patients urdergoing coronary angiography. J Hypertens. 2010;28(4):797-805.
- London GM, Blacher J, Pannier B, Guérin AP, Marchais SJ, Safar ME. Arterial wave reflections and survival in end-stage renal failure. Hypertension. 2001;38(3):434-8.
- Melenovsky V, Borlaug BA, Fetics B, Kessler K, Shively L, Kass DA. Estimation of central pressure augmentation using automated radial artery tonometry. J Hypertens. 2007;25(7):1403-9.

- Yasmin, Brown MJ. Similarities and differences between augmentation index and pulse wave velocity in the assessment of arterial stiffness. QJM. 1999;92(10):595-600.
- Kohara K, Tabara Y, Oshiumi A, Miyawaki Y, Kobayashi T, Miki T. Radial augmentation index: a useful and easily obtainable parameter for vascular aging. Am J Hypertens. 2005;18(1 Pt 2):11S-14S.
- Kelly RP, Millasseau SC, Ritter JM, Chowienczyk PJ. Vasoactive drugs influence aortic augmentation index independently of pulse-wave velocity in healthy men. Hypertension. 2001;37(6):1429-33.
- Sakuragi S, Maruo T, Taniguchi M, Nagase S, Nakamura K, Kusano KF, et al. Radial augmentation index associated with increase in B-type natriuretic peptide in patients with hypertension. Int J Cardiol. 2008;130(3):414-9.
- 22. Wilkinson IB, MacCallum H, Flint L, Cockcroft JR, Newby DE, Webb DJ. The influence of heart rate on augmentation index and central arterial pressure in humans. J Physiol. 2000;525 Pt 1:263-70.
- Nakae I, Matsuo S, Matsumoto T, Mitsunami K, Horie M. Augmentation index and pulse wave velocity as indicators of cardiovascular stiffness. Angiology. 2008;59(4):421-6.
- Williams B, Lacy PS; CAFE and the ASCOT (Anglo-Scandinavian Cardiac Outcomes Trial) Investigators. Impact of heart rate on central aortic pressures and hemodynamics: analysis from the CAFE (Conduit Artery Function Evaluation) study: CAFE-Heart Rate. J Am Coll Cardiol. 2009;54(8):705-13.
- 25. Lang RM, Bierig M, Devereux RB, Flachskampf FA, Foster E, Pellikka PA, et al. Recommendations for chamber quantification: a report from the American Society of Echocardiography's Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology. J Am Soc Echocardiogr. 2005;18(12):1440-63.
- Wojciechowska W, Staessen JA, Nawrot T, Cwynar M, Seidlerová J, Storlarz K, et al. Reference values in white Europeans for the arterial pulse wave record by means of the SphymoCor device. Hypertens Res. 2006;29(7):475-83.
- Shiburi CP, Staessen JA, Maseko M, Wojciechowska W, Thijs L, Van Bortel LM, et al. Reference values for SphygmoCor measurements in South Africans of African ancestry. Am J Hypertens. 2006;19(1):40-6.
- 28. Li Y, Staessen JA, Li LH, Huang QF, Lu L, Wang JG. Reference values for the arterial pulse wave in Chinese. Am J Hypertens. 2008;21(6):668-73.
- Chung JW, Lee YS, Kim JH, Seong MJ, Kim SY, Lee JB, et al. Reference values for the augmentation index and pulse pressure in apparently healthy korean subjects. Korean Circ J. 2010;40(4):165-71.
- Weber T, Auer J, O'rourke MF, Kvas E, Lassnig E, Lamm G, et al. Increased arterial wave reflections predict severe cardiovascular events in patients undergoing percutaneous coronary interventions. Eur Heart J. 2005;26(24):2657-63.
- 31. Nichols WW, Singh BM. Augmentation index as a measure of peripheral vascular disease state. Curr Opin Cardiol. 2002;17(5):543-51.
- Gatzka CD, Kingwell BA, Cameron JD, Berry KL, Liang YL, Dewar EM, et al. Australian Comparative Outcome Trial of Angiotensin-Converting Enzyme Inhibitor and Diuretic-Based Treatment of Hypertension in the Elderly. J Hypertens. 2001;19(12):2197-203.
- Tomiyama H, Yamashina A. Non-invasive vascular function tests: their pathophysiological background and clinical application. Circ J. 2010;74(1):24-33.
- Mitchell GF. Effects of central arterial aging on the structure and function of the peripheral vasculature: implications for end-organ damage. J Appl Physiol. 2008;105(5):1652-60.
- Tomita H, Kawamoto R, Tabara Y, Miki T, Kohara K. Blood pressure is the main determinant of the reflection wave in patients with type 2 diabetes. Hypertens Res. 2008;31(3):493-9.

- 36. Lacy PS, O'Brien DG, Stanley AG, Dewar MM, Swales PP, Williams B. Increased pulse wave velocity is not associated with elevated augmentation index in patients with diabetes. J Hypertens. 2004;122(10):1937-44.
- Ghiadoni L, Penno G, Giannarelli C, Plantinga Y, Bernardini M, Pucci L, et al. Metabolic syndrome and vasculature alterations in normotensive subjects at risk of diabetes mellitus. Hypertension. 2008;51(2):440-5.
- 38. Wilhelm B, Klein J, Friedrich C, Forst S, Pfützner A, Kann PH, et al. Increased arterial augmentation and augmentation index as surrogate parameters for
- arteriosclerosis in subjects with diabetes mellitus and nondiabetic subjects with cardiovascular disease. J Diabetes Sci Technol. 2007;1(2):260-3.
- Wilkinson IB, MacCallum H, Rooijmans DF, Murray GD, Cockcroft JR, McKnight JA, et al. Increased augmentation index and systolic stress in type 1 diabetes mellitus. QJM. 2000;93(7):441-8.
- Schram MT, Henry RM, van Dijk RA, Kostense PJ, Dekker JM, Nijpels G, et al. Increased central artery stiffness in impaired glucose metabolism and type 2 diabetes: the Hoorn Study. Hypertension. 2004;43(2):176-81.